Clinical Trials Logo

Clinical Trial Summary

Multi-site, prospective performance study to determine equivalency between the investigational OneFlow PCD panel on the FACSLyric system versus the final clinical diagnosis.


Clinical Trial Description

Hematology laboratories rely on flow cytometry technology (in addition to classic hematological methods) to aid in screening, diagnosing, and monitoring patients with hematological disorders. High speed and broad applicability of flow cytometry allows for the diagnosis and accurate focus on targets. Currently, there are no general consensus panels being used; as a consequence, the leukemia & lymphoma (L&L) testing remains a single-vial antibody being used, with various in-house laboratory developed tests (LDTs) being used to test patient specimens. Furthermore, the analysis of flow cytometer generated data is not standardized and requires a high level of expertise/training for interpretation of complex data. Therefore, optimized and standardized immunostaining protocols for the diagnosis, classification, and prognostic sub-classification of hematological malignancies are needed. This Investigational panel for plasma cell disorders is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of plasma cell populations on the BD FACSLyric flow cytometer. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having, or suspected of having, plasma cell disorders. Enrollment will occur at up to 8 investigational sites . Data will be acquired from Eligible remnant/leftover specimens on the BD FACSLyric flow cytometer and evaluated by site personnel and expert analysts . The final diagnosis and the affected cell population will be determined by site standard of care . Analysis of data will evaluate identification of normal vs abnormal cell population of the expert & site analysts as compared to the final diagnosis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05032339
Study type Observational
Source Becton, Dickinson and Company
Contact
Status Completed
Phase
Start date May 4, 2021
Completion date October 25, 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03480360 - Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Phase 3
Not yet recruiting NCT06313502 - High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders Phase 1
Recruiting NCT04879043 - Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma Phase 1/Phase 2
Completed NCT02274519 - Novel Support Options in Autologous Stem Cell Transplant for Multiple Myeloma N/A
Active, not recruiting NCT02041325 - Investigation of the Enhancement of the Response to Hepatitis B Vaccine by Lenalidomide (RevlimidTM, CC-5013) in Plasma Cell Dyscrasias Phase 2
Not yet recruiting NCT06330896 - Disease Characteristics and Treatment Response in Plasma Cell Disorders Patients Based on Genetic Abnormalities From Fluorescence In Situ Hybridization and Next Generation Sequencing